COVID-19 clinical trials and the promise of a vaccine

The genome sequence of the SARS-Cov-2 virus was deposited on a National Institutes of Health (NIH) server on Jan. 10, 2020. Within days, scientists all over the world started to use the sequence to make vaccines. Two vaccines are now approved for limited use; eight vaccines are in large-scale phase 3 clinical trials; 13 are in expanded phase 2 safety trials; 21 are moving through phase 1 safety testing. 

More than 135 vaccines are at earlier stages of development. These numbers are being curated by the New York Times and are updated frequently. Search for their Coronavirus Vaccine Tracker; The Times will not fail to keep you updated. 

How the vaccines work

All of the vaccines are designed to present a SARS-CoV-2 spike protein to the human immune system and provoke the production of circulating antibodies and T-cells that kill lung or other cells infected with the virus. After a vaccination or illness, the immune response subsides, but many antibody-producing B cells and cell-killing T cells are banked. When infection occurs, thousands or millions of lymphocytes leap into action and block or minimize the infection. 

With some vaccines the banked cells last a long time; with others, only a few months

The spike protein is a string of about 400 amino acids in a unique order. During its synthesis, the protein folds into a spike shape and is assembled into the SARS-CoV-2. The tip of the spike protein grasps a protruding protein on the surface of human cells and the attached virus is pulled inside, where it unfolds and starts the production of much more virus. 

mRNA as one option

The vaccines in phase 3 testing are all products of genetic manipulation. In one approach, scientists inserted the gene that carries the information for the spike protein into an attenuated animal virus. The Oxford-AstraZeneca group uses a weakened chimpanzee adenovirus with an inserted spike protein gene. They have a Phase III trial in Arizona and lots of other places. The Chinese have four vaccines completing phase 3 and starting general use. 

The method that is most intriguing to me is purely chemical. Recipients get no live or dead virus, which is reassuring for some people. The new method makes the mRNA that provides instructions for the synthesis of the spike protein, but all in a test tube. The scientists wrap the coding mRNA in lipid and inject it into macaques or humans, where it enters cells and uses their protein synthesis capacity to make spike protein. 

In macaques, the mRNA-1273 vaccine successfully defends the host from the coronavirus. This novel vaccine is the product of Tony Fauci’s National Institute of Allergy and Infectious Diseases and a company called Moderna that specializes in RNA-based defenses against infectious disease. The vaccine is in phase 3 trials on 30,000 people. 

Seeking trial volunteers 

The study is recruiting volunteers. 

All clinical trials must register with an organization at the National Library of Medicine at the NIH. Anyone can find the list of clinical trials for a disease or condition at www.ClinicalTrials.gov. If you are interested in joining a SARS-Cov-2 clinical trial, you will also find medical centers involved in the trials at that website  (enter code identifier NCT04470427).

Being a participant requires commitment, because the people running a trial want to know if you produce antibody and new T-cells in response to a vaccination and how long it lasts — which means occasional blood tests. 

They want to know about side effects of inoculation. They are eager to have and are required to have participants of all ages and ethnicities. 

In the Northeast, there are few sites because there is a relatively low level of disease. If we want to test a vaccine, we have to go where disease rates are high—in the United States that means Texas, Alabama, Georgia, Arizona, Missouri and California.

The new techniques now being tested are effective and fast but we have to know about new viruses that will surely appear. New techniques will not do us much good if we ignore pandemic preparedness plans, eliminate virus surveillance programs, leave the World Health Organization, disparage the CDC and denigrate scientists and physicians who are trying to keep us alive. 

 

Richard Kessin Ph.D is Professor Emeritus of Pathology and Cell Biology at Columbia University’s Irving Medical Center. He can be reached at Richard.kessin@gmail.com.

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

A scenic 32-mile loop through Litchfield County

Whenever I need to get a quick but scenic bicycle ride but don’t have time to organize a group ride that involves driving to a meeting point, I just turn right out of my driveway. That begins a 32-mile loop through some of the prettiest scenery in northern Litchfield County.

I ride south on Undermountain Road (Route 41 South) into Salisbury and turn right on Main Street (Route 44 West). If I’m meeting friends, we gather at the parking area on the west side of Salisbury Town Hall where parking is never a problem.

Keep ReadingShow less
Biking Ancramdale to Copake

This is a lovely ride that loops from Ancramdale north to Copake and back. At just over 23 miles and about 1,300 feet of elevation gain, it’s a perfect route for intermediate recreational riders and takes about two hours to complete. It’s entirely on quiet roads with little traffic, winding through rolling hills, open countryside, picturesque farms and several lakes.

Along the way, you’ll pass a couple of farmstands that are worth a quick visit. There is only one hill that might be described as steep, but it is quite short — probably less than a quarter-mile.

Keep ReadingShow less
Taking on Tanglewood

Aerial view of The Shed at Tanglewood in Lenox, Mass.

Provided

Now is the perfect time to plan ahead for symphonic music this summer at Tanglewood in Lenox, Massachusetts. Here are a few highlights from the classical programming.

Saturday, July 5: Shed Opening Night at 8 p.m. Andris Nelsons conducts the Boston Symphony Orchestra as Daniil Trifonov plays piano in an All-Rachmaninoff program. The Piano Concerto No. 3 was completed in 1909 and was written specifically to be debuted in the composer’s American tour, at another time of unrest and upheaval in Russia. Trifonev is well-equipped to take on what is considered among the most technically difficult piano pieces. This program also includes Symphonic Dances, a work encapsulating many ideas and much nostalgia.

Keep ReadingShow less
James H. Fox

SHARON — James H. Fox, resident of Sharon, passed away on May 30, 2025, at Vassar Brothers Hospital.

Born in New York, New York, to Herbert Fox and Margaret Moser, James grew up in Hastings-on-Hudson, New York. He spent his summers in Gaylordsville, Connecticut, where he developed a deep connection to the community.

Keep ReadingShow less